Quantcast

Latest Glioma Stories

2014-07-28 23:05:11

National Brain Tumor Society connects biotech company to researchers’ technology. Hershey, PA & Boston, MA (PRWEB) July 28, 2014 Immunomic Therapeutics, Inc. (ITI) has entered into collaboration agreements with two researchers to further develop potential treatments for glioblastoma multiforme (GBM), the most common and deadly malignant brain tumor, in combination with their patented vaccine platform, LAMP-vax. The agreements, recently executed by ITI and Duke University, are based...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-08 08:32:31

("Leading Edge" Gamma Knife Treatment, led by Christopher Duma, M.D., FACS and his team of researchers, offers hope to patients with Glioblastoma Multiforme) NEWPORT BEACH, Calif., July 8, 2014 /PRNewswire/ -- A study on the effects of an aggressive and strategic treatment called "Leading Edge" radiosurgery offers hope to patients diagnosed with life-threatening brain cancer. The study identifies the pathways of invasion of malignant glioma cells and provides a map in which a...

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-06-27 14:56:01

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) A clinical phase I trial to examine the safety of the vaccine against gliomas based on mutant IDH1 in human patients is planned Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. "Low-grade gliomas", which grow comparatively slowly, spread in a diffuse manner across the...

2014-06-27 12:26:56

HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal(®)) and Antineoplaston AS2-1 injections (Astugenal(®)), at the 16(th) International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement...

2014-06-24 08:31:08

U.S. Phase 2a Clinical Trial in Recurrent Glioblastoma to Initiate in Early 2015 SYDNEY, June 24, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV(TM) nanocells packaged with doxorubicin for the treatment...

2014-06-17 11:02:54

Ohio State University Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Viruses that are designed to kill cancer cells – oncolytic viruses – have shown promise in clinical trials for the...

2014-06-17 08:29:17

SAN DIEGO, June 17, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma. The FDA gives Fast Track status to facilitate the development of new products for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs,...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related